Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Yawn

posted on May 24, 2017 10:37AM

Yawn. It's been very quiet on the Zenith end of things. They are attending the ASCO meeting in Chicago late next week according to the schedule, but from what I gathered they are only attending not presenting. Zenith is on the schedule for presenting at BIO International in San Diego next month: Tuesday June 20th, 3:30 PM San Diego time. Possibly a corporate update/webcast????? By the way, the one year anniversary of the start of dosing in the ZEN-3694 trial is coming up on June 15, 2017!